Products
Latest News
FAQ
Log in
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Newest First
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Phase 2
Recruiting
Conditions
Solid Tumor
Precision Medicine
Interventions
Drug: Olaparib tablet
Drug: Target Gene
Drug: Temozolomide capsule
Drug: Anlotinib
Drug: Trametinib tablet
Drug: Dabrafenib
Drug: Vebreltinib Enteric Capsules
Drug: Alpelisib Pill
Drug: Sacituzumab Govitecan-Hziy 180 MG
Drug: Lenvatinib Capsules
Drug: Pazopanib Pill
Drug: Palbociclib Pill
Drug: Chidamide
Drug: PD-1/PD-L1/PD-1&CTLA4 inhibitor
Subscribe
First Posted Date
2024-12-18
Last Posted Date
2024-12-18
Lead Sponsor
Tianjin Medical University Second Hospital
Target Recruit Count
300
Registration Number
NCT06739395
Locations
🇨🇳
Tianjin Medical Unversity Second Hospital, Tianjin, Tianjin, China
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy